San Francisco, 20 December 2023: The Report Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics Disease Diagnostics), By Region, And Segment Forecasts, 2018 - 2025

The global autoimmune disease diagnostics market is expected to reach a value of USD 5.0 billion by 2025, based on a new report by Grand View Research, Inc. Government organizations along with related associations strive to curb such high healthcare costs and simultaneously provide improved diagnostic and therapeutic solutions to the patients. This has resulted in increased funding by the NIH for R&D programs related to autoimmune diseases.

Moreover, the presence of favorable government initiatives aimed at curbing the incidence of these diseases and developing viable diagnostic & treatment options is expected to drive market growth over the forecast period.

Growing volume of autoimmune diagnostic procedures has heightened the need for instruments and facilities rendering faster and effective results. In an attempt to cater to ever-increasing procedure volumes, diagnostic laboratories are rapidly moving toward automation. Lab automation helps decrease workload via rapid turnaround times and helps generate standardized & reproducible results.

Immune system performs the crucial role of protecting the body from diseases and infections arising due to the entry of foreign particles in the human body. The immune system produces antibodies specific to these antigens and destroys them before they cause a disorder.

However, in case of some individuals, the immune system attacks its own healthy cells by mistake further leading to the occurrence of autoimmune disorders such as rheumatoid arthritis, diabetes type 1, and Systemic lupus erythematosus (SLE). Early diagnosis of such disorders is very important for assessing various treatment alternatives, thereby curbing healthcare expenditure on the same.

Increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies coupled with demand for rapid diagnostics is the key driver accentuating growth.

Research and diagnostics institutes over the globe are undertaking initiatives in compliance with government organizations owing to the rising prevalence of autoimmune disorders and the consequent rise in healthcare expenditure. According to the data published by the National Institutes of Health (NIH), these disorders have been ranked as one of the top ten disorders leading to increased mortality rates among women.

Request sample report of Autoimmune Disease Diagnostics Market@ https://www.grandviewresearch.com/industry-analysis/autoimmune-disease-diagnostics-industry

Advanced technologies are paving a way for accurate diagnostics

There are more than 80 types of autoimmune diseases reported across the globe. Many of these have similar set of symptoms making it difficult for healthcare professionals to detect them in time. The most common symptoms of these diseases are muscle strain, fluctuating fever, and fatigue. Inflammation is a classic sign of these disease that is likely to cause heat, redness, swelling, and throbbing pain. Healthcare professionals often prescribe various tests to derive accurate results during diagnosis.

Highly trusted tests by the clinicians for proper diagnosis while detecting & treating autoimmune disorders are autoantibody, antinuclear antibody, complete blood count, C-reactive protein, and Erythrocyte Sedimentation Rate tests.

Introduction of advanced technology is the blockbuster attraction of this market. Key players are undertaking high R&D initiatives for developing novel and accurate techniques for early diagnosis. One such example is the usage of third-generation cyclic citrullinated peptide technology by Inova Diagnostics for accurate diagnosis of rheumatoid arthritis patients from a pool of people exhibiting similar symptoms.

Further key findings from the study suggest:

• Localized autoimmune disease diagnostics was the largest segment in 2015 owing to high usage for type 1 diabetes and idiopathic thrombocytopenic purpura
• Type 1 diabetes is estimated to grow at a significant growth rate of over 4.0% in the localized disease type segment
• Systemic disease diagnostics is anticipated to witness lucrative CAGR of around 5.0% over the forecast period due to increasing R&D for the development of novel diagnostic biomarkers for the treatment of rheumatoid arthritis and systemic lupus erythematosus
• Rheumatoid arthritis is one of the most recurring autoimmune disorders further demanding a high amount of rapid diagnostics for exploring better alternative treatments
• North America was the largest regional market in 2015. The high market penetration rate of technologically advanced products and increased lab automation rate are some of the factors contributing to its large share
• Asia Pacific region is anticipated to grow at the fastest CAGR of above 4.0% over the forecast period owing to increasing focus on type 1 diabetes diagnosis

The introduction of technological advancements and increasing lab automation rates are estimated to fuel market growth. Clinicians are adopting advanced technology in order to conduct multiple tests at the same time with faster and more precise results.

Slow turnaround time associated with the usage of conventional disease diagnostic techniques and the presence of a lesser number of standardized tests for over 80 disease types are some of the shortcomings encouraging laboratories to move toward automation.

Moreover, the presence of favorable government initiatives is anticipated to positively boost market dynamics. Organizations such as the Autoimmunity Centers of Excellence, Cooperative Study Group for Autoimmune Disease Prevention, and North American Rheumatoid Arthritis Consortium are actively involved in educating patients and healthcare professionals regarding proper diagnosis and treatment.

Report Scope

Growing awareness amongst patients concerning these diseases is expected to drive the market growth. Survey results conducted by the American Autoimmune Related Diseases Association, Inc. (AARDA) in 2013 suggest that the ability of an American patient to name an autoimmune disease has increased by 10% (as compared to the last conducted survey). This increase can be attributed to extensive public awareness campaigns undertaken such as the Autoimmune Awareness Month held in March 2014 and National Awareness Campaign by the AARDA.

List of Key Players of Autoimmune Disease Diagnostics

• Hoffmann-La Roche Ltd
• Siemens Healthineers
• Abbott Laboratories
• Beckman Coulter, Inc.
• SQI Diagnostics
• Quest Diagnostics
• EUROIMMUN AG
• Diagnostics
• Inova Diagnostics, Inc.
• Crescendo Bioscience, Inc.
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Hemagen Diagnostics, Inc.